BOSTON – Mintz advised underwriters on the accomplished completion of LB Pharmaceuticals Inc.’s $285 million initial public offering (IPO), marking a meaningful event in the biotechnology sector. the offering provides LB Pharmaceuticals with crucial capital to advance its research and development programs.
the IPO involved the sale of 19,000,000 shares of LB Pharmaceuticals’ common stock at $15.00 per share, generating approximately $285 million in gross proceeds for the company, excluding underwriting discounts and expenses. An additional option allows underwriters to purchase up to 2,850,000 more shares at the IPO price, less applicable discounts and commissions. This influx of capital positions LB Pharmaceuticals for continued growth and innovation in its therapeutic areas. Shares commenced trading on the Nasdaq Global Market on September 11, 2025, under the ticker symbol “LBRX.”
Leerink Partners, Piper Sandler, and Stifel served as joint bookrunning managers for the offering.
The Mintz team advising on the transaction was led by William Hicks, John Rudy, Alok Choksi, Sam silver, Gianna Nappi, Gretchen Goyette, and Chris Kinney. Joanne Hawana provided critical regulatory guidance, Serge Banini offered specialized intellectual property counsel, and Gregg Benson delivered essential tax advice. Mintz professionals contributing to the IPO are located across the firm’s Boston, New York, Washington, DC, and San Diego offices.
